Inventage Lab Inc is a Korea-based company principally engaged in the pharmaceutical business. The Company owns the platforms applied to the development and mass production of long-acting injections and drug delivery of genetic materials. The Company is engaged in the research, manufacture and sale of human medicines used for male pattern baldness, dementia, prostate cancer and others. It is also engaged in the research, manufacture and sale of veterinary medicines such as combination drugs, chemical castration agents and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
30/06/26	₩39,500.00	-0.63%	51,513
29/06/26	₩39,750.00	+11.81%	72,269
26/06/26	₩35,550.00	-3.66%	80,629
25/06/26	₩36,900.00	-8.44%	72,701
24/06/26	₩40,300.00	+4.95%	107,170

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 30/06/2026			5-day change	1st Jan Change
39,500.00 ^KRW	-0.63%		+2.86%	-53.09%

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-15	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI

Market Cap	524B 339M 296M 274M 255M 481M 32.02B 490M 3.28B 1.27B 15.8B 1.27B 1.24B 55.05B	P/E 2024	-11.5x	P/E 2025	-110x
Enterprise Value	519B 335M 293M 271M 253M 476M 31.7B 485M 3.25B 1.26B 15.64B 1.26B 1.23B 54.49B	EV / Sales 2024	106x	EV / Sales 2025	356x
Free-Float	78.93%	Yield 2024 *	-	Yield 2025	-

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-15	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI
03-08	Inventage Lab, Inc. announced that it has received KRW 8.5 billion in funding	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 37.25 billion in funding from a group of investors	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 8.5 billion in funding	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 52.74724455 billion in funding from a group of investors	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
02-25	Inventage Lab, Inc. agreed to acquire an additional 12.79% stake in Quratis Inc. for KRW 13.5 billion.	CI
12-10	Inventage Lab Seeks Approval for Phase 2 Trial of Alopecia Drug in Australia	MT
22/09/25	Inventage Lab, Inc.(KOSDAQ:A389470) added to S&P Global BMI Index	CI
11/03/25	Inventage Lab, Inc. announced that it has received KRW 9.9999925 billion in funding from PEACE to S KOREA Co., Ltd	CI
11/03/25	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
20/02/25	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI

1 day	-0.63%
1 week	+2.86%
1 month	-22.40%
3 months	-39.69%
6 months	-53.09%
Current year	-53.09%

Inventage Lab, Inc. Share Price

Stocks

A389470

KR7389470006

Pharmaceuticals

Valuation: Inventage Lab, Inc.

Chart: Inventage Lab, Inc.

Latest news : Inventage Lab, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Inventage Lab, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	33,600	41,000
1 month	33,600	53,000
Current year	33,600	101,700
1 year	28,550	101,700
3 years	8,800	101,700
5 years	8,440	101,700
10 years	8,440	101,700

Manager	Title	Age	Since
Ju-Hee Kim CEO	Chief Executive Officer	52	13/05/2015
Byeong-Yul Jeong DFI	Director of Finance/CFO	55	-
Chan-Hee Jeon CTO	Chief Tech/Sci/R&D Officer	57	-

Director	Title	Age	Since
Ju-Hee Kim BRD	Director/Board Member	52	13/05/2015
Choong-Ho Ryu BRD	Director/Board Member	56	-
Dong-Hoon Kim BRD	Director/Board Member	56	-

Date	Insider	Type	Quantity	% Market Cap.
07/08/25	Se Yeon Kim	Fiscal year	10,000	0.0996%
07/08/25	Dong Seok Park	Fiscal year	8,000	0.0796%
07/08/25	Dong Seok Park	Fiscal year	8,000	0.0796%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INVENTAGE LAB, INC.	-0.63%	+2.86%	+23.44%	+342.83%	342M
ELI LILLY AND COMPANY	-2.48%	+8.34%	+53.87%	+155.75%	1,097B
JOHNSON & JOHNSON	-1.76%	+6.23%	+66.27%	+53.44%	622B
ABBVIE INC.	-1.05%	+7.19%	+35.57%	+86.77%	449B
ROCHE HOLDING AG	+0.83%	+4.18%	+31.11%	+23.88%	334B
ASTRAZENECA PLC	-1.38%	+3.75%	+39.33%	+25.04%	294B
NOVARTIS AG	+0.30%	+2.56%	+31.62%	+40.64%	286B
NOVO NORDISK A/S	-0.10%	+2.23%	-28.43%	-42.77%	213B
AMGEN INC.	+0.44%	+4.35%	+29.69%	+63.10%	195B
GILEAD SCIENCES, INC.	+0.01%	+1.03%	+13.95%	+63.93%	157B
Average	-0.55%	+4.85%	+29.64%	+81.26%	364.71B
Weighted average by Cap.	-1.12%	+7.04%	+40.91%	+77.69%

	2024	2025
Net sales	1.78B 1.15M 1.01M 930K 868K 1.63M 109M 1.66M 11.16M 4.33M 53.72M 4.33M 4.23M 187M	2.94B 1.9M 1.66M 1.53M 1.43M 2.69M 179M 2.74M 18.39M 7.14M 88.54M 7.13M 6.97M 308M
Net income	-17B -10.98M -9.61M -8.87M -8.27M -15.59M -1.04B -15.86M -106M -41.3M -512M -41.23M -40.31M -1.78B	-8.46B -5.46M -4.78M -4.41M -4.12M -7.76M -516M -7.9M -52.94M -20.55M -255M -20.52M -20.06M -888M
Net Debt	-23.96B -15.48M -13.55M -12.5M -11.66M -21.98M -1.46B -22.37M -150M -58.23M -722M -58.14M -56.84M -2.52B	-5.33B -3.44M -3.01M -2.78M -2.59M -4.89M -325M -4.97M -33.34M -12.94M -160M -12.92M -12.64M -559M